CD80
T-lymphocyte activation antigen CD80
Also known as: B7-1, B7.1, CD28LG, CD28LG1, CD80_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P33681
- Gene
- CD80
- Ensembl
- ENSG00000121594
- Chromosome
- 3
- Canonical length
- 288 aa
- Protein class
- CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Secretome location
- Intracellular and membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy. [provided by RefSeq, Aug 2011]
Canonical amino-acid sequenceUniProt
288 residues, UniProt reviewed canonical sequence.
>P33681|CD80
1 MGHTRRQGTS PSKCPYLNFF QLLVLAGLSH FCSGVIHVTK EVKEVATLSC GHNVSVEELA
61 QTRIYWQKEK KMVLTMMSGD MNIWPEYKNR TIFDITNNLS IVILALRPSD EGTYECVVLK
121 YEKDAFKREH LAEVTLSVKA DFPTPSISDF EIPTSNIRRI ICSTSGGFPE PHLSWLENGE
181 ELNAINTTVS QDPETELYAV SSKLDFNMTT NHSFMCLIKY GHLRVNQTFN WNTTKQEHFP
241 DNLLPSWAIT LISVNGIFVI CCLTYCFAPR CRERRRNERL RRESVRPVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CD80 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 6.4 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 6.4 nTPM
- lymph node: 5.2 nTPM
- appendix: 5 nTPM
- spleen: 3.2 nTPM
- lung: 2.8 nTPM
- thymus: 2.4 nTPM
Single-cell type
- cdc: 31 nCPM
- macrophages: 23 nCPM
- b-cells: 22 nCPM
- kupffer cells: 18 nCPM
- monocytes: 7.9 nCPM
- megakaryocytes: 6.2 nCPM
Immune cell
- memory B-cell: 1.4 nTPM
- T-reg: 1.3 nTPM
- non-classical monocyte: 0.4 nTPM
- intermediate monocyte: 0.2 nTPM
- naive B-cell: 0.2 nTPM
- memory CD4 T-cell: 0.1 nTPM
Brain region
- choroid plexus: 1.7 nTPM
- thalamus: 1.4 nTPM
- medulla oblongata: 1.1 nTPM
- spinal cord: 1.1 nTPM
- white matter: 1.1 nTPM
- cerebral cortex: 0.9 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CD80.
Disease | AutoantibodyPubMed
Conditions in which antibodies against CD80 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for CD80 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
11 publications
- Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule.
1995 · Eur J Immunol · RCR 2.6 · 131 citations - Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules.
2002 · J Neuroimmunol · RCR 1.1 · 56 citations - Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein.
1997 · J Exp Med · RCR 0.9 · 52 citations - B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies.
1999 · J Immunol · RCR 0.7 · 41 citations - Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis.
2022 · Arthritis Res Ther · RCR 0.6 · 8 citations
Show 6 more
- A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease.
2011 · Int J Immunopathol Pharmacol · RCR 0.5 · 19 citations - B7-1 and B7-2 co-stimulatory molecules are required for mercury-induced autoimmunity.
2002 · Clin Exp Immunol · RCR 0.4 · 20 citations - Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.
2015 · Mol Med Rep · RCR 0.4 · 12 citations - Autoantibodies against CD80 in patients with COPD.
2016 · Clin Transl Immunology · RCR 0.4 · 9 citations - Effects of anti-B7 monoclonal antibodies on humoral immune responses.
1999 · J Autoimmun · RCR 0.3 · 12 citations - Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.
2000 · Int J Cancer · RCR 0.2 · 12 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.9
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.75
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell surface receptor signaling pathway
- cellular response to lipopolysaccharide
- immune response
- intracellular signal transduction
- negative regulation of T cell activation
- negative regulation of T cell mediated immunity
- negative regulation of T cell proliferation
- negative regulation of T cell receptor signaling pathway
- positive regulation of DNA-templated transcription
- positive regulation of granulocyte macrophage colony-stimulating factor production
- positive regulation of interleukin-2 production
- positive regulation of peptidyl-tyrosine phosphorylation
- positive regulation of signal transduction
- positive regulation of T cell proliferation
- positive regulation of T cell receptor signaling pathway
- positive regulation of T-helper 1 cell differentiation
- T cell activation
- T cell costimulation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Immunoglobulin V-set domain
- CD80-like, immunoglobulin C2-set
- Immunoglobulin-like fold
- Immunoglobulin-like domain superfamily
- T-cell Activation and Immune Regulation Protein
- Immunoglobulin V-set domain
- CD80-like C2-set immunoglobulin domain
- CD80, IgC-like domain
- CD80, immunoglobulin variable domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CD80 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CD80 as an antibody target. Whether an autoantibody or antibody against CD80 could matter depends on whether native CD80 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CD80 is annotated at the cell surface, where native CD80 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CD80 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...